Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has reached a key milestone in its ongoing imaging collaboration with Massachusetts General Hospital, as patient enrollment in a pilot study has hit the halfway mark and early imaging data show a promising signal in multiple sclerosis (MS) lesions. The study is evaluating a novel positron emission tomography (PET) imaging tracer that could help differentiate between reversible nerve damage and permanent damage, potentially supporting the development of the company’s MS drug candidate, Lucid-MS.
Multiple sclerosis is one of the most common neurological diseases affecting young adults worldwide. Approximately 2.9 million people are living with the disease globally, and nearly one million of those individuals are in the United States. Most people are diagnosed between the ages of 20 and 40, meaning MS strikes during some of the most productive years of a person’s life. The ability to track disease progression and distinguish between different types of nerve damage is critical for developing effective treatments.
The imaging study uses a PET tracer designed to bind to specific targets in the brain, allowing researchers to visualize and differentiate between active inflammation, demyelination, and remyelination. Early results have shown a meaningful signal in MS lesions, suggesting the tracer may be able to identify areas of reversible damage. This could provide a valuable tool for assessing the efficacy of Lucid-MS, which aims to promote myelin repair.
“Reaching the halfway mark in patient enrollment and seeing encouraging preliminary data is a significant step forward,” said a company spokesperson. “If validated, this imaging technique could transform how we monitor MS progression and treatment response.”
The study is part of Quantum BioPharma’s broader focus on neurodegenerative and metabolic disorders. The company is listed on the NASDAQ under the ticker QNTM and on the Canadian Securities Exchange under QNTM. For more information, visit the company’s newsroom at https://nnw.fm/QNTM.
This announcement comes amid growing interest in advanced imaging techniques for MS. The ability to non-invasively track myelin repair could accelerate drug development and provide more personalized treatment options for patients. With nearly 3 million people affected worldwide, the need for better diagnostic and therapeutic tools is urgent.
Investors and researchers will be watching for further data as the study progresses. The company expects to complete enrollment and report final results in the coming months.
